Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh - obinutuzumab - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - leucemia limfocitară cronică (llc)gazyvaro în asociere cu clorambucil este indicat pentru tratamentul pacienților adulți cu netratați anterior, leucemia limfocitară cronică (llc) și cu comorbidități ceea ce le face nepotrivite pentru full-doza terapia pe bază de fludarabină (a se vedea secțiunea 5. limfom folicular (fl)gazyvaro în asociere cu chimioterapie, urmat de gazyvaro tratamentului de întreținere la pacienții care au prezentat un răspuns, este indicat pentru tratamentul pacienților cu netratați anterior avansate limfom folicular. gazyvaro în combinație cu bendamustina urmat de gazyvaro de întreținere este indicat pentru tratamentul pacienților cu limfom folicular (fl) care nu au răspuns sau care au progresat în timpul sau până la 6 luni după tratamentul cu rituximab sau rituximab-conțin regim.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche ltd - obinutuzumabum - concentrat pentru soluţie perfuzabilă - 1000 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemie, limfocitică, cronică, celule b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

roche pharma ag - germania - obinutuzumabum - conc. pt. sol. perf. - 1000mg - anticorpi monoclonali si conjugati anticorp medicament

Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - agenți antineoplazici - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agenți antineoplazici - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Uniunea Europeană - română - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

johnson & johnson srl - ibrutinibum - capsule - 140 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astrazeneca ab - acalabrutinibum - capsule - 100 mg